Share
4,823 Posts.
lightbulb Created with Sketch. 2365
clock Created with Sketch.
11/07/20
16:24
Share
Originally posted by awichiu:
↑
So the normal procedure of things is, when you want to see a doctor, you ring up the clinic to make an appointment, then you go to the clinic, then you see the doctor, then you pay the bill etc. Now with telehealth, when you want to see the doctor, you ring the clinic to make an appointment, or you make an online booking for that appointment. At the time of the appointment you click into a video call (you'll be instructed on how to do that by the clinic) hosted by Healthdirect or Coviu, then the doctor join the call, then you consult over the Healthdirect platform. For a respiratory problem, the doctor may then decide to order ResAppDx. Healthdirect then asks you to pay $11 for the test, and then gives you a code. You then punch in the code into the ResAppDx app on your phone to run the test. Then the doctor gets the result, and discuss with you the diagnosis and the next steps. With Phenix, you don't call your normal doctor, you just directly go to them for the whole package. I haven't used it but from what others say here it's a virtual respiratory clinic wear you use ResAppDx first before you even consult the doctor? I'm not knowledgeable in this. So essentially, to answer your question, Healthdirect / Coviu are telehealth platforms for GPs to teleconsult on. You don't go to the platform to find the doctors you want to consult. You find your own doctors, and already have your own doctors. And then they tell you what to do next. Am I making sense?
Expand
Thank you. I'm happy to accept that my assumption that I would go looking for a telehealth provider in the first instance, and pick a clinic second is wrong. I guess when I have a genuine health concern my first thought would be to contact the last clinic I went to, if I still lived nearby. And at present, with restrictions in place, the clinic would (as you say) be likely to divert me onto a telehealth path. I'm disappointed that I've not been able to independently verify the prominence given to ResappDx (or respiratory telehealth) to form my own view on the likely impact on revenue for Resapp. I'll have to hold my curiousity in check for the September quarterly, same as everybody else.
Originally posted by awichiu:
↑
Your estimate doesn't stack up In response to your statements 1) "You happen by chance to pick a doctor that provides telehealt " - I don't know of any clinic these days that doesn't offer telehealth 2) "The telehealth platform used by the doctor just happens to offer ResappDx " - Coviu / Healthdirect is pretty much the dominant force in the Australian telehealth market, and you can use ResAppDx via these platforms. So there's a very good chance that any doctor who does telehealth will have access to ResAppDx. And that's a lot of doctors. 3) "The doctor just happens to decide to ask you to do the ResappDx test " - Now I find this comment rather insulting. Doctors don't just "happen" to decide to ask for a test. Our decisions to order any tests are evidence based and driven by necessity. In relation to respiratory consults over telehealth, the principal consideration is whether we can safely diagnose an acute respiratory illness without clinical examination, and if not, should we do acute respiratory consults over telehealth at all? The answer before ResAppDx is probably no, we shouldn't do acute respiratory consults over telehealth at all because it's not safe. But with ResAppDx, the answer would be yes we can, provided that we use ResAppDx. So the decision is not random, it's based on best available evidence. The current best available evidence based tool is ResAppDx.
Expand
Thank you again, and I apologise for the "rather insulting" implication that doctors "just happen" to request particular tests.